NATURETIN-10 (bendroflumethiazide) by Bristol Myers Squibb is clinical pharmacology nadolol nadolol is a nonselective beta-adrenergic receptor blocking agent. Approved for hypertension, to lower blood pressure. First approved in 1959.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
NATURETIN-10 (bendroflumethiazide) is a thiazide diuretic oral tablet approved in 1959 for hypertension management. It lowers blood pressure by increasing sodium and chloride excretion through the distal renal tubule, reducing extracellular fluid volume and peripheral vascular resistance. The drug is indicated as monotherapy or adjunctive therapy to reduce elevated blood pressure.
As an approaching loss-of-exclusivity generic, this product faces significant commercial headwinds; brand team size likely contracting with focus on defending niche positioning or transitioning to combination formulations.
CLINICAL PHARMACOLOGY Nadolol Nadolol is a nonselective beta-adrenergic receptor blocking agent. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood…
Worked on NATURETIN-10 at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg
Working on NATURETIN-10 at this lifecycle stage offers limited upside but stable, specialized expertise in legacy hypertension management and generic market dynamics. Career trajectory typically focuses on defending market share against generics, managing cost-of-goods optimization, or transitioning to combination therapy development.